PMID: 44871Jan 1, 1979

Amineptine, a new antidepressant: pharmacological review (author's transl)

L'Encéphale
J C Poignant

Abstract

Amineptine is a tricyclic derivative with a 7-carbon chain of aminoacids. Chemical alterations of the aminoacid chain have revealed its importance in the shaping of the pharmacological effects. The drug is rapidly absorbed. Amineptine is metabolised principally by beta-hydroxylation of the chain. The pharmacological profile at different doses is as follows: a. 0.1 mg/kg: reduction of exploratory behaviour, b. 1 mg/kg: reduction of serum prolactin level, c. 5 mg/kg: potentiation of L-5 HTP, d. 10 mg/kg: antagonism of the effects of reserpine and of tetrabenazine, e. increased activity and social behaviour, EEG alerting effect limited to 1 hour and increase in paradoxical sleep (15 to 20 mg/kg). This pharmacological profile suggests an effect of amineptine upon certain dopamine structures. At synapse, neurobiochemistry confirms a mechanism of inhibition of DA incorporation and inhibition of uptake and/or release of 5 HT. Amineptine is virtually devoid of peripheral activity, particularly anticholinergic Amineptine may be indicated for the treatment of depression where retardation is dominant.

Related Concepts

Amineptin sodium salt
Behavior, Animal
5-Hydroxytryptophan
Serotonin
Brain
Uptake
Alert brand of caffeine
Anticholinergic [EPC]
Dibenzocycloheptenes
Synapses

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at an accelerated rate. In MS, it has been shown that there is a reduction in synaptic density, which presents a potential target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

Artificial Intelligence in Cardiac Imaging

Artificial intelligence (ai) techniques are increasingly applied to cardiovascular (cv) medicine in cardiac imaging analysis. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

Social Learning

Social learning involves learning new behaviors through observation, imitation and modeling. Follow this feed to stay up to date on the latest research.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Single Cell Chromatin Profiling

Techniques like ATAC-seq and CUT&Tag have the potential to allow single cell profiling of chromatin accessibility, histones, and TFs. This will provide novel insight into cellular heterogeneity and cell states. Discover the latest research on single cell chromatin profiling here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells.